Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw its shares crater by as much as 21% today on exceptionally high volume. This drop was triggered by …
Analyst nearly doubles price target between Gocovri pricing and better prospects in Multiple Sclerosis arena.
Lead asset for ADMS indicates promising prospects in Parkinson’s along with valuable opportunity in MS.
Adamas Puts CRL Fears to Rest with Gocovri (Amantadine) Approval
A Peek Into Three Volatile Biotech Stocks: ADMS, XOMA, KMDA
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) investors are busy throwing a party this evening, following the news that the drug maker has won FDA approval …
